Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model

Cancer Letters

Volumn 274, Issue 2, 2009, Pages 271-278

  Koto, Kazutaka ^a   Horie, Naoyuki ^a   Kimura, Shinya ^b   Murata, Hiroaki ^a   Sakabe, Tomoya ^a   Matsui, Takaaki ^a   Watanabe, Motonobu ^b   Adachi, Souichi ^b   Maekawa, Taira ^b   Fushiki, Shinji ^a   Kubo, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Metastasis; Neovascularization; Osteosarcoma; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; LUNG METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOSARCOMA; PRENYLATION; PRIORITY JOURNAL;

ANIMALS; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LUNG NEOPLASMS; MICE; OSTEOSARCOMA; PROTEIN PRENYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE;

EID: 58149296145     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.026     Document Type: Article

References (43)

1. Arndt C.A., and Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341 (1999) 342-352
2. Bacci G., Ferrari S., Longhi A., et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur. J. Cancer 37 (2001) 32-38
3. Kempf-Bielack B., Bielack S.S., Jürgens H., et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J. Clin. Oncol. 23 (2005) 559-568
4. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 (2004) 3-13
5. Kuroda J., Kimura S., Segawa H., et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 (2003) 2229-2235
6. Matsumoto S., Kimura S., Segawa H., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
7. Yuasa T., Nogawa M., Kimura S., et al. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin. Cancer Res. 11 (2005) 853-859
8. Sato K., Yuasa T., Nogawa M., et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br. J. Cancer 95 (2006) 1354-1361
9. Hiraga T., Williams P.J., Ueda A., Tamura D., and Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 10 (2004) 4559-4567
10. Daubiń F., Le Gall C., Gasser J., Green J., and Clėzrdin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst. 99 (2007) 322-330
11. Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., and Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 (2005) 2522-2529
12. Horie N., Murata H., Nishigaki Y., et al. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett. 238 (2006) 111-118
13. Horie N., Murata H., Kimura S., et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anti-cancer agents against osteosarcoma. Brit. J. Cancer 96 (2007) 255-261
14. Unni K. Dahlin's Bone Tumors: General Aspects & Data on 11087 Cases. fifth ed. (1996), Lippincott-Raven, Philadelphia, PA
15. Asai T., Ueda T., Itoh K., et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer 76 (1998) 418-422
16. Yang J., Mani S.A., Donaher J.L., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (2004) 927-939
17. Fidler I.J. The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
18. Nogawa M., Yuasa T., Kimura S., et al. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol. Res. 15 (2005) 1-9
19. Nogawa M., Yuasa T., Kimura S., et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 217 (2005) 243-253
20. Takeshita H., Kusuzaki K., Tsuji Y., et al. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209. Anticancer Res. 18 (1998) 739-742
21. Kimura S., Maekawa T., Hirakawa K., Murakami A., and Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 55 (1995) 1379-1384
22. Nogawa M., Yuasa T., Kimura S., et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 115 (2005) 978-985
23. Ueda T., Araki N., Mano M., et al. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone. J. Clin. Pathol. 55 (2002) 853-858
24. Sato K., Kimura S., Segawa H., et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116 (2005) 94-99
25. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006) 6222-6230
26. Coleman R.E. Bisphosphonates for the prevention of bone metastases. Semin. Oncol. 29 (2002) 43-49
27. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., and Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med. Oncol. 22 (2005) 195-201
28. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
29. Green J.R. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 44 (2005) 282-292
30. Unni K.K. Osteosarcoma of bone. J. Orthop. Sci. 3 (1998) 287-294
31. Dvorak H.F., Nagy J.A., Berse B., et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann. N.Y. Acad. Sci. 667 (1992) 101-111
32. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
33. Fournier P.S., Boissier S., Filleur J., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
34. Nam J.S., Ino Y., Sakamoto M., and Hirohashi S. Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Jpn. J. Cancer Res. 93 (2002) 1020-1028
35. Hacker U., and Perrimon N. RhoGEF2 encodes a member of the Dbl family of oncogenes and controls cell shape changes during gastrulation in Drosophila. Genes Dev. 12 (1998) 274-284
36. van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Lowik C.W., and Papapoulos S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (2003) 805-811
37. Monkkonen H., Auriola S., Lehenkari P., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Brit. J. Pharmacol. 147 (2006) 437-445
38. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42 (2002) 1228-1236
39. Bauss F., Wagner M., and Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J. Rheumatol. 29 (2002) 990-998
40. Santini D., Vincenzi B., Dicuonzo G., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9 (2003) 2893-2897
41. Woodward J.K., Coleman R.E., and Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 16 (2005) 11-19
42. Budman D.R., and Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70 (2006) 147-153
43. Mitsiades C.S., Bogdanos J., Karamanolakis D., Milathianakis C., Dimopoulos T., and Koutsilieris M. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res. 26 (2006) 3693-3700